Absci and Kennedy Institute partner to expedite immunotherapies development
Pharmaceutical Technology
MAY 12, 2023
Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies. The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.
Let's personalize your content